Comparison Overview

Chugai Pharma USA, Inc.

VS

Ipca Laboratories Limited

Chugai Pharma USA, Inc.

JP
Last Update: 2025-12-10
View Profile
Between 800 and 849
http://www.chugai-pharm.co.jp/hc/ss/english/index.html

Chugai’s strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai-originated, innovative new drug candidates. Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties. For a list of Chugai’s current research projects please visit: http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 227
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Ipca Laboratories Limited

125 Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, IN, 400067
Last Update: 2025-12-09
Between 750 and 799
https://www.ipca.com/

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 13,205
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/chugai-pharmaceutical-co--ltd-.jpeg
Chugai Pharma USA, Inc.
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/ipca.jpeg
Ipca Laboratories Limited
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Chugai Pharma USA, Inc.
100%
Compliance Rate
0/4 Standards Verified
Ipca Laboratories Limited
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Chugai Pharma USA, Inc. in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Ipca Laboratories Limited in 2025.

Incident History — Chugai Pharma USA, Inc. (X = Date, Y = Severity)

Chugai Pharma USA, Inc. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Ipca Laboratories Limited (X = Date, Y = Severity)

Ipca Laboratories Limited cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/chugai-pharmaceutical-co--ltd-.jpeg
Chugai Pharma USA, Inc.
Incidents

No Incident

https://images.rankiteo.com/companyimages/ipca.jpeg
Ipca Laboratories Limited
Incidents

No Incident

FAQ

Chugai Pharma USA, Inc. company demonstrates a stronger AI Cybersecurity Score compared to Ipca Laboratories Limited company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Ipca Laboratories Limited company has disclosed a higher number of cyber incidents compared to Chugai Pharma USA, Inc. company.

In the current year, Ipca Laboratories Limited company and Chugai Pharma USA, Inc. company have not reported any cyber incidents.

Neither Ipca Laboratories Limited company nor Chugai Pharma USA, Inc. company has reported experiencing a ransomware attack publicly.

Neither Ipca Laboratories Limited company nor Chugai Pharma USA, Inc. company has reported experiencing a data breach publicly.

Neither Ipca Laboratories Limited company nor Chugai Pharma USA, Inc. company has reported experiencing targeted cyberattacks publicly.

Neither Chugai Pharma USA, Inc. company nor Ipca Laboratories Limited company has reported experiencing or disclosing vulnerabilities publicly.

Neither Chugai Pharma USA, Inc. nor Ipca Laboratories Limited holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Chugai Pharma USA, Inc. company nor Ipca Laboratories Limited company has publicly disclosed detailed information about the number of their subsidiaries.

Ipca Laboratories Limited company employs more people globally than Chugai Pharma USA, Inc. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Chugai Pharma USA, Inc. nor Ipca Laboratories Limited holds SOC 2 Type 1 certification.

Neither Chugai Pharma USA, Inc. nor Ipca Laboratories Limited holds SOC 2 Type 2 certification.

Neither Chugai Pharma USA, Inc. nor Ipca Laboratories Limited holds ISO 27001 certification.

Neither Chugai Pharma USA, Inc. nor Ipca Laboratories Limited holds PCI DSS certification.

Neither Chugai Pharma USA, Inc. nor Ipca Laboratories Limited holds HIPAA certification.

Neither Chugai Pharma USA, Inc. nor Ipca Laboratories Limited holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
References
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
References
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N
References